Oncology Institute (NASDAQ:TOI) Coverage Initiated at BTIG Research

BTIG Research began coverage on shares of Oncology Institute (NASDAQ:TOI) in a research report sent to investors on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the stock.

Oncology Institute Stock Performance

Shares of TOI stock opened at $3.04 on Thursday. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The company’s fifty day moving average price is $1.86 and its 200-day moving average price is $0.95. The stock has a market cap of $229.70 million, a PE ratio of -3.90 and a beta of 0.04. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $3.50.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%. The business had revenue of $104.41 million for the quarter.

Insider Buying and Selling at Oncology Institute

In other Oncology Institute news, Director Mark L. Pacala purchased 90,562 shares of the stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $1.04 per share, with a total value of $94,184.48. Following the completion of the acquisition, the director now directly owns 224,971 shares in the company, valued at $233,969.84. This trade represents a 67.38% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders purchased 122,258 shares of company stock worth $127,148. 8.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC raised its holdings in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after purchasing an additional 109,769 shares during the last quarter. Virtu Financial LLC purchased a new stake in Oncology Institute in the fourth quarter worth approximately $41,000. Renaissance Technologies LLC grew its position in Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after purchasing an additional 12,000 shares during the period. XTX Topco Ltd raised its stake in Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock valued at $63,000 after buying an additional 18,448 shares during the last quarter. Finally, Citizens Financial Group Inc. RI bought a new position in shares of Oncology Institute during the 1st quarter valued at $71,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.